Here's a thought: Whatever FDA hashes out with Amarin will not be limited to the 2nd District. We've been concentrating on the jurisdictional limits of the recent ruling, but if FDA comes to some agreement with AMRN about truthful, non-misleading conduct, it would have to be considered a universal agreement. Still, I bet FDA can't do it, and it will be in the hands of the judge again.